Collegium Pharmaceutical, Inc. (COLL) Operating Margin
- Operating margin · 12 months: Value 19.48%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 19.48% | Operating income / revenue. Period ending 2026-06-30. $157.44M ÷ $808.21M × 100 ≈ 19.48% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 157.44M USD | Operating Income (Loss) |
| Revenue | 808.21M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 323.12M USD | Cost of Goods and Services Sold |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | 327.69M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $157.44M | $808.21M | $323.12M | (m) | $327.69M | 19.48% |
| 2026-03-31 | $188.84M | $796.33M | $313.15M | (m) | $294.73M | 23.71% |
| 2025-12-31 | $179.64M | $780.57M | $317.31M | (m) | $284.80M | 23.01% |
| 2025-09-30 | $156.99M | $757.07M | $323.90M | (m) | $280.25M | 20.74% |
| 2025-06-30 | $129.74M | $707.01M | $306.22M | (m) | $275.11M | 18.35% |
| 2025-03-31 | $142.11M | $664.28M | $281.07M | (m) | $244.80M | 21.39% |
| 2024-12-31 | $169.90M | $631.45M | $254.10M | $0.00 | $210.36M | 26.91% |
| 2024-09-30 | $193.47M | $599.25M | $225.56M | (m) | $180.21M | 32.29% |
| 2024-06-30 | $203.65M | $576.65M | $219.45M | (m) | $153.56M | 35.32% |
| 2024-03-31 | $191.81M | $566.92M | $226.70M | (m) | $148.41M | 33.83% |
| 2023-12-31 | $166.96M | $566.77M | $240.60M | $0.00 | $159.21M | 29.46% |
| 2023-09-30 | $117.03M | $546.64M | $265.31M | (m) | $164.30M | 21.41% |
| 2023-06-30 | $92.48M | $536.95M | $277.09M | (m) | $167.37M | 17.22% |
| 2023-03-31 | $67.96M | $524.95M | $286.56M | (m) | $170.43M | 12.95% |
| 2022-12-31 | $33.32M | $463.93M | $254.44M | $3.98M | $172.19M | 7.18% |
| 2022-09-30 | $-12.56M | $361.68M | $203.31M | $5.59M | $160.76M | -3.47% |
| 2022-06-30 | $-18.88M | $313.50M | $167.87M | $7.04M | $152.90M | -6.02% |
| 2022-03-31 | $-13.58M | $272.90M | $129.38M | $10.50M | $142.01M | -4.98% |
| 2021-12-31 | $17.63M | $276.87M | $126.25M | $9.45M | $118.96M | 6.37% |
| 2021-09-30 | $66.75M | $325.78M | $129.53M | $10.31M | $119.18M | 20.49% |
| 2021-06-30 | $72.22M | $326.11M | $127.79M | $11.01M | $115.09M | 22.15% |
| 2021-03-31 | $72.36M | $321.23M | $124.78M | $10.04M | $114.05M | 22.53% |
| 2020-12-31 | $56.23M | $310.02M | $130.18M | $9.77M | $113.83M | 18.14% |
| 2020-09-30 | $38.86M | $307.95M | $147.29M | $9.70M | $112.10M | 12.62% |
| 2020-06-30 | $12.86M | $301.71M | $163.06M | $10.05M | $115.74M | 4.26% |
| 2020-03-31 | $-8.70M | $298.70M | $182.02M | $10.01M | $115.36M | -2.91% |
| 2019-12-31 | $-23.75M | $296.70M | $193.66M | $10.34M | $116.45M | -8.00% |
| 2019-09-30 | $-10.37M | $295.93M | $174.30M | $10.19M | $121.81M | -3.51% |
| 2019-06-30 | $-15.19M | $293.16M | $173.55M | $9.61M | $125.19M | -5.18% |
| 2019-03-31 | $-17.47M | $291.18M | $171.74M | $9.38M | $127.53M | -6.00% |
| 2018-12-31 | $-20.68M | $280.41M | $165.68M | $8.66M | $126.76M | -7.38% |
| 2018-09-30 | $-49.27M | (m) | (m) | $8.61M | $121.40M | (m) |
| 2018-06-30 | $-51.51M | (m) | (m) | $8.77M | $110.71M | (m) |
| 2018-03-31 | $-65.48M | (m) | (m) | $8.71M | $101.49M | (m) |
| 2017-12-31 | $-75.45M | (m) | (m) | $8.57M | $92.76M | (m) |
| 2017-09-30 | $-85.44M | (m) | (m) | $9.71M | $93.03M | (m) |
| 2017-06-30 | $-98.45M | (m) | (m) | $10.89M | $93.84M | (m) |
| 2017-03-31 | $-101.67M | (m) | (m) | $13.02M | $91.95M | (m) |
| 2016-12-31 | $-94.08M | (m) | (m) | $14.95M | $80.63M | (m) |
| 2016-09-30 | $-75.94M | (m) | (m) | $13.15M | (m) | (m) |
| 2016-06-30 | $-58.76M | (m) | (m) | $13.25M | (m) | (m) |
| 2016-03-31 | $-38.86M | (m) | (m) | $10.59M | (m) | (m) |
| 2015-12-31 | $-26.91M | (m) | (m) | $7.97M | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-17.66M | (m) | (m) | $14.96M | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-16.04M | (m) | (m) | $14.16M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |